Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As the US shutdown rolls on, blockbuster launches line up for 2019
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Topping 2018 drug approvals will be a tall order
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
Pharma news over the Christmas period
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
DBV Technologies investors go into shock with filing withdrawal
DBV Technologies’ decision to pull its Viaskin Peanut filing leaves the door open for Aimmune Therapeutics to clean up.
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.